Diabetes Drug Injection Helps Obese People Lose Weight And Keep It Off
By: Anne Harding
Published: July 01, 2015 05:27pm ET on LiveScience.
The diabetes drug liraglutide can help obese people who don't have diabetes lose weight and keep it off, new findings confirm.
Researchers found that 63 percent of study participants given liraglutide for 56 weeks lost at least 5 percent of their body weight — the amount experts agree is needed to make a difference in obesity-related health problems — whereas just 27 percent of the placebo group lost that much.
"It is a very effective drug. It seems to be as good as any of the others on the market, so it adds another possibility for doctors to...
Source: Science - The Huffington Post - July 6, 2015 Category: Science Source Type: news
Medical News Today: Diabetes drug proves effective weight-loss aid
Compared with placebo, a diabetes drug recently given approval for weight loss - liraglutide (Saxenda) - produced an average loss of 5.6 kg at a daily dose of 3.0 mg. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 6, 2015 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news
Diabetes drug helps people lose weight
Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, helped obese people lose an average of 18 pounds (eight kilograms), according to a new study published in the New England Journal of Medicine.
Yahoo (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 3, 2015 Category: Endocrinology Source Type: news
Injectable diabetes medicine drives down weight, too, research finds
The diabetes medication liraglutide helped more than twice as many obese subjects in a clinical trial lose 5% of their body weight, and more than three times as many lose a tenth of their body weight, compared with subjects taking a placebo, according to new research. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - July 2, 2015 Category: Science Authors: Melissa Healy Source Type: news
Diabetes drug Liraglutide helps obese people lose more than a stone
Liraglutide, marketed under the brand name Saxenda, is already available to treat obese patients in the US. A new study found it helped people lose 18lbs over the course of 56 weeks. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2015 Category: Consumer Health News Source Type: news
Publication Boosts Liraglutide for Obesity, but Cost an Issue Publication Boosts Liraglutide for Obesity, but Cost an Issue
One-year data, now published, demonstrate significant weight loss and improved metabolic parameters with liraglutide in overweight and obese adults without diabetes at baseline. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 2, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Published Results Confirm Weight Loss With Saxenda (CME/CE)
(MedPage Today) -- Now in a major journal, findings from big, year-long study show liraglutide bested placebo (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 2, 2015 Category: Cardiology Source Type: news
Liraglutide Facilitates Weight Reduction in Nondiabetic Patients (FREE)
By Allan S. Brett, MD
Dr. Brett is editor-in-chief of NEJM Journal Watch General Medicine, from which this story was adapted. See full coverage at the link below.Liraglutide helps nondiabetic patients lose weight, but gastrointestinal side effects are common, according to an industry-supported study in the New … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 2, 2015 Category: Primary Care Source Type: news
Is There a Link Between Liraglutide and Pancreatitis?Is There a Link Between Liraglutide and Pancreatitis?
Does liraglutide therapy contribute to the incidence of acute or chronic pancreatitis among type 2 diabetics? Find out about the possible connection. Diabetes Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Liraglutide and Atherothrombotic Risk in Women With PCOSLiraglutide and Atherothrombotic Risk in Women With PCOS
Does this GLP-1 receptor agonist reduce CV risk and promote weight loss in women with PCOS? BMC Endocrine Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
What Is Saxenda, the New 'Blockbuster' Weight Loss Medication?
There is a new "blockbuster" weight loss drug on the market, Saxenda, and it is available in many U.S. pharmacies this month. It is perhaps the most important weight loss medication ever developed. Novo Nordisk Inc., a very big and very old Danish pharmaceutical company, has launched the new drug after months of anticipation by consumers, clinicians and market watchers.
Saxenda is very different from all other weight loss drugs. For one thing, it is a once-a-day injection, like some diabetes medications, instead of a pill. For another, it works in an entirely different way, mimicking a naturally-occurring hormone that y...
Source: Healthy Living - The Huffington Post - May 21, 2015 Category: Consumer Health News Source Type: news
Lau on Liraglutide: Is It Safe? AACE Video
NASHVILLE (MedPage Today) -- Exclusive AACE Video Conference Reporter coverage, with Hallway Takes from David C.W. Lau, PhD, on Liraglutide Safety; Shashank R. Joshi, MD, on the Saragliptin Trial; and Carolina Solis-Herrera, MD, on the Dapagliflozin Trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 18, 2015 Category: Cardiology Source Type: news
Novo Nordisk weighs diabetes drug's use in fatty liver disease
COPENHAGEN (Reuters) - Novo Nordisk is looking into recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease, a hot area for pharmaceutical development. (Source: Reuters: Health)
Source: Reuters: Health - May 18, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its...
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin.(PRWeb April 23, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12671977.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 24, 2015 Category: Pharmaceuticals Source Type: news
Two Diabetes Drugs May Ease Fatty Liver DiseaseTwo Diabetes Drugs May Ease Fatty Liver Disease
One option, liraglutide, is already on the market; the second is an experimental sodium-glucose cotransporter-2 inhibitor. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 24, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
